June 23, 2017
RARECast: Summit Pursues A Different Approach to Treating Duchenne
Read More
January 19, 2017
Why Health Insurers Won't Cover this $300,000-a-year Rare Disease Drug
Read More
November 2, 2016
cTAP Announces Two Research Publications Categorizing and Predicting Disease Progression in Duchenne Muscular Dystrophy
Read More
September 30, 2016
RARECast: A Controversial Approval for a Duchenne Drug and What Lies Ahead
Read More
September 17, 2015
Rare Disease Reports: FDA Accepts Sarepta’s Sarepta’s NDA for Eteplirsen. PDUFA Date Set
Read More
August 13, 2014
FDA Boosts Sarepta With Prognosis for its Rare Disease Drug
Read More
May 1, 2013
Highlights from the World Orphan Drug Congress 2013
Read More
October 3, 2012
Sarepta Therapeutics Clinical Trial Results with Eteplirsen Brings Kids with Duchenne Muscular Dystrophy Closer to Treatment
Read More
X